Company ProfilePremium

Boryung Corporation (formerly Boryung Pharmaceutical Co., Ltd.)

Company Profile Analysis

Ticker: 003850.KS주식회사 보령

ESOMAR 23 Corporate BadgeISO Certifications Badge
Boryung Corporation - Company showcase

Year Founded & Workforce

1957

1,553 Employees

Boryung Corporation logo

Boryung Corporation Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Boryung Corporation Overview

Boryung is a mid-sized, prescription-led Korean pharmaceutical company that crossed KRW 1 trillion in annual revenue for the first time in FY2024 and ranks around eighth among Korean traditional pharma groups by sales. Its franchise rests on three pillars: (1) Kanarb (fimasartan), Korea's most commercially successful home-grown new drug and the base of a family of hypertension and dyslipidaemia combinations; (2) an oncology business built through "Legacy Brands Acquisition" (LBA) — buying and in-sourcing manufacture of off-patent originator brands such as Gemzar, Alimta and, since June 2026, the global Taxotere business acquired from Sanofi; and (3) a cytotoxic and oral-solid manufacturing hub at Yesan Campus that is now being monetised through global CDMO contracts. Under third-generation owner-CEO Jay Kim, the company is reorganising into a manufacturing/R&D/global parent with a separately incorporated commercial subsidiary, while also making long-dated bets on space life sciences through Axiom Space and its BRAX Space joint venture.


What the company does

Boryung manufactures, imports, licenses and sells finished pharmaceuticals, overwhelmingly to the Korean prescription (ETC) market. Its revenue derives from four broad activities:

  1. Self-developed branded drugs — chiefly the Kanarb family (fimasartan mono and fixed-dose combinations), which represented about 15% of FY2024 revenue (KRW 150.9 billion, iNews24, 2025) and 15.9% of FY2025 revenue (HuffPost Korea, Aug 2026), plus incrementally modified drugs and first-to-file generics (e.g., Lenvanib, a lenvatinib generic approved February 2025).

  2. Acquired originator ("LBA") brands — Gemzar (gemcitabine, Korean rights from Eli Lilly, 2020), Zyprexa (olanzapine, Korean rights from Lilly, 2021), Alimta (pemetrexed, Korean rights from Lilly, 2022) and Taxotere (docetaxel, global business in 19 countries/regions from Sanofi, closed May/June 2026). Boryung transfers manufacturing of these products in-house to Yesan, improving gross margin (Dealsite, 2025; Daily Pharm, 2025–2026).

  3. In-licensed / co-promoted products ("merchandise") — e.g., Lilly's Trulicity distribution, HK inno.N's K-CAB co-promotion from 2024 (IBK Securities, Jan/Apr 2024), Organon's Atozet exclusive distribution from August 2026 (Daily Pharm headline, Aug 2026), and biosimilars. The 2023 Daily Pharm interview with then co-CEO Chang Doo-hyun put merchandise at about 40.6% of sales, low by Korean standards.

  4. Contract manufacturing (CDMO) and exports — Alimta injectable supply to Lotus (Taiwan, contract Dec 2024, first shipment May 2026), Zyprexa tablets to Cheplapharm for up to 46 countries (contract Jul 2025, exports from Q4 2026), Alimta to Zuellig Pharma for seven Southeast Asian markets (contract Oct 2025, supply from 2027), and Taxotere global supply including a seven-year USD 277.1 million contract with China's Yifan Pharmaceutical (Sept 2026).

Consumer/OTC brands historically associated with Boryung — Gelfos (antacid) and Yonggaksan (cough/expectorant) — are manufactured by Boryung, while their OTC marketing and sales are conducted by Boryung Consumer Healthcare, a 100% subsidiary of the parent Boryung Holdings (not of the listed company) since 2018 (Daily Pharm, Apr 2020; Dealsite, Apr 2024). Gelfos holds roughly 30% of the Korean OTC antacid market (Daily Pharm, Jun 2026).

Business and revenue model

Revenue typeDescriptionShare of revenue
Product sales — own manufactured goodsKanarb family, in-sourced LBA brands, generics, OTC goods supplied to affiliate~59.4% of sales at 3Q22 (Daily Pharm, Feb 2023); later figure not publicly disclosed
Merchandise sales — purchased finished goodsIn-licensed/co-promoted products (K-CAB, Trulicity, Atozet etc.)~40.6% (Daily Pharm, Feb 2023); later figure not publicly disclosed
Contract manufacturing / CDMOLotus, Cheplapharm, Zuellig; prior domestic contract manufacturingNot separately disclosed; "Other (export, contract mfg.)" was KRW 75.1bn in FY2023 (IBK Securities)
Licensing / royaltyKanarb out-licensing (Latin America, Russia, China, SE Asia)Not publicly disclosed (small)
Subscription—0%

Company's own description

In recruitment and corporate materials, Boryung describes itself as a business that began as Boryung Pharmacy in 1957, entered drug manufacturing in 1963 and grew with Yonggaksan and Gelfos, launched Kanarb in 2011, adopted the LBA strategy in 2020, and passed KRW 1 trillion in sales in 2024, with an ambition to become Korea's leading pharmaceutical company (Remember career postings, 2025–2026). Its mission statement is to become a company indispensable to human health. Its English-language press materials since 2022 have described the group as a "healthcare investment company" (KED Global, Jan 2024; Axiom Space press release, Jan 2024).

Independent characterisation

Boryung is best understood as a Korean specialty-brand consolidator with captive manufacturing: rather than funding high-risk novel-drug discovery, it buys proven off-patent originator brands, in-sources their production to capture gross margin, and then reuses the resulting regulatory dossiers and EU-GMP capacity to sell manufacturing services and the brands themselves internationally. Kanarb provides a domestic cash engine but is now in post-patent erosion. The space-healthcare programme is a capital-allocation choice by the controlling family rather than an operating business — it has generated no reported revenue (Daily Pharm, Sept 2026).

Value-chain position: Formulation, manufacturing (finished dose; not API), regulatory ownership, marketing and distribution. Customers: hospitals (tertiary and secondary), clinics, pharmacies via wholesalers; global pharma partners (CDMO); national distributors abroad (Taxotere). End-markets: cardiovascular/metabolic (hypertension, dyslipidaemia, diabetes), oncology (cytotoxics, targeted generics, supportive care), CNS (Zyprexa ~75.7% of CNS sales in Q1 2026, Dealsite TV, Jun 2026), respiratory/anti-infectives (Mucomyst, Maxipime), gastroenterology.

Strategy

Stated strategy (themes from management communications)

  1. Become an "indispensable" supplier of strategic essential medicines — secure in-house production capacity for drugs critical to national supply chains, then use that capacity to drive profit and global growth (Feb 2025 board statement; Nov 2024 rights-issue rationale).

  2. LBA (Legacy Brands Acquisition) — acquire proven originator brands, internalise manufacturing, improve formulations (e.g., liquid Gemzar and Alimta), and now acquire global rather than Korea-only rights (Taxotere).

  3. "Great Kanarb" — continuously launch new Kanarb-based combinations; target was KRW 200bn family sales by 2026 (Daily Pharm, Feb and Jul 2023). On disclosed run-rates (~KRW 150–160bn), this target appears unlikely to be met in FY2026.

  4. Global CDMO for cytotoxics and oral solids — monetise Yesan's EU-GMP capacity (Lotus, Cheplapharm, Zuellig).

  5. Commercial specialisation — BPS spin-off (2027) to in-license third-party blockbusters and use CSOs for non-core products; AI-enabled sales (Daily Pharm headline, Aug 2026).

  6. Space life sciences ("Humans In Space") — positioned by the CEO as the company's second pillar alongside pharma (Daily Pharm, Mar 2025).

Initiatives in the last 24 months

DateInitiativeDetail
Nov 2024KRW 175bn equity raiseKRW 50bn facilities, KRW 50bn acquisitions of other companies, KRW 75bn working capital; fund plant expansion, essential-medicine supply, global CDMO, space
Dec 2024 – Oct 2025Three global CDMO contractsLotus, Cheplapharm, Zuellig
2,025Partial outsourcing of sales to CSOsFocus own reps on large brands (Daily Pharm, Sept 2026)
Sept 2025 – Jun 2026Taxotere global acquisitionFirst Korean acquisition of a big-pharma originator oncology business for global sale
May 2026Kanarb Jet launchTriple combo with statin + ezetimibe
Jun 2026All-employee equity schemeKRW 20bn treasury purchase
Sept 2026BPS spin-off2030 targets: +26 own products, +16 in-licensed, >10% domestic share
Sept 2026Yifan Taxotere China contractUSD 277.1m, 7 years
OngoingESG2050 carbon-neutral roadmap, third-party GHG verification, NDC 2035 response

Cost programmes with quantified targets: not publicly disclosed.

Medium-term targets / guidance

  • Earlier target of KRW 1 trillion revenue by 2026 (KED Global, Jul 2023) — achieved in FY2024.

  • 2024 guidance reportedly KRW 1 trillion revenue and KRW 85bn operating profit (Daily Pharm headline, 2024) — revenue met, operating profit missed (KRW 70.5bn).

  • FY2026 formal guidance: not publicly disclosed in sources reviewed.

  • BPS 2030 targets as above.

Products & Services

Cardiovascular & metabolic (ETC)

ProductDescriptionTarget customerLaunch / latestNotes
Kanarb (fimasartan) 30/60/120 mgARB antihypertensive; indications: essential hypertension and reduction of proteinuria in hypertensive type 2 diabetic CKDCardiologists, GPsLaunched 2011Substance patent expired 2023; proteinuria-use patent runs to 2036 (Dealsite, Feb 2026). Price cut notified Jun 2025 (30 mg KRW 439→307; 60 mg 642→450; 120 mg 758→531), currently stayed pending appeal
Kanarb PlusFimasartan + hydrochlorothiazideSame—Family member
DukarbFimasartan + amlodipineSame—Price-cut litigation also covers Dukarb (Daily Pharm, Feb 2026)
Dukarb PlusTriple fixed-dose combinationSame—Family member
TuveroFimasartan + rosuvastatinSame—Family member
DukaroFimasartan + amlodipine + rosuvastatinSame—Family member (IBK, 2021)
AkarbFimasartan + atorvastatinSame—Family member (IBK, 2021)
Kanarb JetFimasartan + atorvastatin + ezetimibeHypertension with dyslipidaemiaLaunched May 2026KRW 3.7bn initial stock delivered in Q2 2026; Daily Pharm headline reports a 42% share within a month (segment basis not specified)
LacorKanarb-based combination——Marketed by Dongwha Pharm (Daily Pharm, 2021)
Diabetes portfolioGenerics/IMDs (unnamed)Endocrinologists, GPs2023 onwardsQ1 2025 sales KRW 4.5bn, +65.9% YoY (Dealsite, Apr 2025)
Trulicity (dulaglutide)GLP-1 RA, Lilly (distribution)DiabetesImportedSupply shortages noted in 2024 (IBK)
AtozetEzetimibe/atorvastatin, OrganonDyslipidaemiaExclusive distribution from Aug 2026Daily Pharm headline, Aug 2026

Oncology (ETC — ONCO division)

ProductDescriptionLaunch / acquisitionNotes
Taxotere (docetaxel)Originator cytotoxic taxane (breast, lung, prostate, gastric, head & neck cancers); WHO Essential MedicineGlobal business in 19 countries/regions acquired from Sanofi; revenue from June 20262024 global sales EUR 70m (KRW 115.4bn) (Hankyung, Sept 2025); China is largest market; manufacturing to transfer to Yesan
Gemzar (gemcitabine)Originator cytotoxic (pancreatic, lung, others)Korean rights from Lilly May 2020Liquid formulation launched; in-house manufacture
Alimta (pemetrexed)Originator antifolate (NSCLC, mesothelioma)Korean rights from Lilly 2022In-house production; liquid formulation launched; CDMO supply to Lotus (2026) and Zuellig (from 2027)
Ditaxel (docetaxel generic)Leading generic docetaxel in Korea—Must be divested within 6 months of 4 Jun 2026 (extendable 6 months) under KFTC remedy
Lenvanib (lenvatinib)First generic of Lenvima (HCC, thyroid, RCC)Approved Feb 2025; reimbursed May 2025Boryung invalidated/avoided all non-substance Lenvima patents
Cabozantinib generic (planned)Generic of CabometyxEarliest launch moved to 2030Partial invalidation of unlisted patent, May 2026
Palbociclib generic (planned)Generic of IbranceNear-termDaily Pharm, May 2026
Belkin (bortezomib)Generic for multiple myelomaYesan production from Dec 2020Daily Pharm, Jan 2021
Oxaliplatin and other cytotoxic genericsYesan-produced injectables2021 onwardsDaily Pharm, Jan 2021
Xeloda (capecitabine), Genexol (paclitaxel), Megace, CamptoImported/partner oncology brands historically marketedPre-2021IBK, 2021
Zepzelca (lurbinectedin)Small-cell lung cancerPlanned 2023 launchDaily Pharm, Feb 2023
Xbrik (denosumab biosimilar, Samsung Bioepis)Bone metastasisLaunched in KoreaSecondary AI-aggregated news summary
Oncology biosimilars & supportive careVarious2022 onwardsDaily Pharm, Jul 2023

CNS, respiratory, anti-infective, GI (ETC)

ProductDescriptionNotes
Zyprexa (olanzapine)Atypical antipsychoticKorean rights from Lilly 2021; in-house production completed 2024–2025; 75.7% of CNS sales in Q1 2026; supplied to Cheplapharm for up to 46 countries from Q4 2026
MucomystBronchitis / mucolyticQ1 2025 sales KRW 6.0bn, +5.5% YoY
MaxipimeAntibiotic (cefepime)Q1 2025 sales KRW 3.7bn, +14.7% YoY
StogarAnti-ulcerFirst product produced at Yesan (2020)
K-CAB (tegoprazan)P-CAB for acid-related disease, HK inno.NCo-promotion from 2024

OTC / consumer (manufactured by Boryung, marketed by affiliate Boryung Consumer Healthcare)

BrandDescriptionNotes
Gelfos M / Gelfos LLiquid antacid (aluminium phosphate, magnesium hydroxide, simethicone); Gelfos L adds a digestive ingredient~30% share of Korean OTC antacid market; FY2024 brand sales KRW 18.5bn; 12-pack launched Jun 2026
Yonggaksan / Yonggaksan CoolPowder/granule cough and expectorantHeritage brand produced since 1967
YonggaksuGargle / oral rinseBrand extension

Services

ServiceDescriptionCustomers
Cytotoxic injectable CDMOEU-GMP isolator lines at YesanLotus (Taiwan), Zuellig Pharma (SE Asia)
Oral solid CDMOZyprexa tabletsCheplapharm (Germany/Switzerland)
Space life-science research accessVia BRAX on future Axiom StationKorean research and commercial users (pre-revenue)

Pricing models are not publicly disclosed beyond reimbursement prices set by the Korean MOHW/HIRA.

Financial Narrative

All figures consolidated K-IFRS, KRW billions unless stated. Source: S&P Global Market Intelligence via StockAnalysis.com (income statement updated Aug 2026; balance sheet and cash flow FY figures). Ratios marked (c) are computed.

Margins and growth

Revenue CAGR FY2021–FY2025 (c): 12.85%. Operating income CAGR FY2021–FY2025 (c): 11.9%.

Quarterly trajectory (most recent six quarters)

Sources: Dealsite (Q1 2025, Apr 2025; Q4 2025 corrected, Feb 2026; Q2 2026, Aug 2026); SK Securities via StockHub (Q1 2026). Q2 2025 derived from Q2 2026 YoY deltas (Dealsite); Q3 2025 derived as FY2025 less other quarters (computed). H1 2026: revenue KRW 535.0bn (+8.7%), operating income KRW 44.0bn (+21.1%), gross profit KRW 199.2bn (+8.2%), OPM 8.2% — record half-year (Money Today, Aug 2026).

Balance sheet

Latest (30 Jun 2026, S&P Global via StockAnalysis): cash KRW 135.0bn, total debt KRW 388.9bn, net debt KRW 253.8bn, equity KRW 894.8bn, BVPS KRW 10,636.5 — reflecting the ~KRW 280bn Taxotere payment at closing.

Cash flow

TTM to 30 Jun 2026: OCF KRW 150.2bn, capex KRW 24.9bn, FCF KRW 125.3bn; purchase of intangibles KRW 288.1bn (Taxotere).

Ratios

TTM (Jun 2026, S&P Global): ROE 14.38%, ROA 3.19%, ROIC 5.80%, current ratio 1.71, debt/equity 0.43, debt/EBITDA 3.24, interest coverage 5.49.

Commentary on trends, inflections and drivers

Revenue. Boryung compounded revenue at ~12.9% per year from FY2021 to FY2024, driven by (i) Kanarb family line extensions; (ii) the LBA oncology brands, which lifted H1 2023 oncology sales 48% YoY; and (iii) large in-licensed/co-promoted volumes, notably K-CAB from 2024 (IBK estimated KRW 27.9bn in Q1 2024 alone). FY2025 growth stalled at 0.03% because the Q4 2025 restatement cut revenue by KRW 18.6bn to book expected price-cut clawbacks on Kanarb (Dealsite, Feb 2026); underlying FY2025 revenue before that adjustment would have been roughly 1.9% higher. Growth resumed in 2026 (H1 +8.7%), with Taxotere contributing from June.

Gross margin. The step-down from ~41% (FY2023) to ~35.7% (FY2024) coincided with the onset of large merchandise volumes (K-CAB co-promotion) that carry low margins; the mix effect, not price erosion, explains most of the change (inference from IBK 2024 data). Margin recovery began in FY2025 (36.6%) and accelerated in Q1 2026 when gross margin reached 63% on a product-revenue basis per SK Securities (different basis — StockHub summary), helped by in-house Alimta production and liquid Gemzar.

Operating income. Operating margin peaked at 7.9% in FY2023, then compressed as R&D rose 26.5% in FY2025 to KRW 65.1bn and the Kanarb provision was booked. Daily Pharm reported that, excluding the Kanarb deduction, Q4 2025 operating income would have been KRW 29.1bn rather than −KRW 0.6bn. Cumulative Kanarb-related refund provisions were reported at KRW 32.3bn (Daily Pharm, 2026). H1 2026 operating margin recovered to 8.2% even with continued provisioning and a 54.7% jump in quarterly amortisation to KRW 8.1bn after Taxotere.

Below the line. Net income is volatile because of investment revaluations (space portfolio, other securities) and FX. FY2024 benefited from a tax credit (negative tax expense of KRW 6.7bn) and FX gains; TTM June 2026 net income of KRW 120.6bn includes KRW 52.6bn FX gains and KRW 21.9bn investment gains, so the trailing P/E of 5.8x materially overstates recurring earnings power.

Balance sheet. FY2022 net debt jumped to KRW 190bn after Alimta (KRW 102.7bn intangible purchase) and working-capital build. The November 2024 KRW 175bn equity injection from the owner's vehicle restored a net-cash position, which was then redeployed: in FY2025 Boryung raised KRW 199.4bn of long-term debt ahead of the Taxotere closing, and long-term investments rose by KRW 188bn (composition not detailed in aggregated data). After closing, net debt stood at KRW 253.8bn (Jun 2026) — roughly 2.1x TTM EBITDA.

Cash flow. Working capital absorbed KRW 62bn in FY2022 and KRW 56bn in FY2023 as inventory more than doubled from FY2021 (LBA brand stock-building and in-sourcing). FY2025 was the first year of release (+KRW 29.3bn), lifting FCF to a five-year high of KRW 110.9bn. The cash conversion cycle remains long (~130 days), typical of Korean pharma with hospital receivables, but has improved from its FY2023 peak.

Returns. ROE has hovered between 7% and 9% and ROIC between 5% and 7% — below what the "1 trillion club" peers with proprietary blockbusters earn (Hanmi, Daewoong), and constrained by the space investments and equity dilution in FY2024.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityRelationshipNotes

Boryung Holdings Co., Ltd.

Parent (~50.66%)

Unlisted; Jay Kim owns 51.31% after May 2026 merger (Dealsite TV, May 2026); FY2025 standalone operating loss KRW 0.26bn, net profit KRW 10.46bn (NewsSpace, 2026)

Boryung Partners

Former shareholder (21.10%)

Absorbed into Holdings 1 May 2026

BRAX Space Corporation

Subsidiary (51%)

JV with Axiom Space (49%); CEO Jack (Dong-ju) Lim

Boryung Pharma Solution

Planned 100% subsidiary

From 4 Jan 2027, subject to EGM

Boryung Consumer Healthcare

Sister company (100% Boryung Holdings)

OTC marketing of Gelfos, Yonggaksan; CEO Seo Jung-wook (Jan 2025)

Vigencell

Associate/affiliate

—

Boryung Biopharma

Former affiliate

80% sold by owner-side vehicle to Eugene PE/KDB PE consortium for ~USD 231m (KED Global, Jun 2024)

Revenue by Segment

Business line / franchiseFY2023FY2024FY2025

Total consolidated revenue (KRW Bn)

859.61,017.11,017.4

Kanarb family revenue (KRW Bn)

—150.9—

Other: export and contract manufacturing (KRW Bn)

75.1——

Total exports (KRW Bn)

——12.6

Gelfos exports (KRW Bn)

2.17.23.5

Yesan oncology injectable production value (KRW Bn)

—21.643.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Revenue by Segment (Quarterly)

Franchise metric (KRW Bn)Q4 2023Q1 2024Q1 2025Q2 2025Q2 2026

Kanarb family revenue

50.435.538.538.138.8

Alimta revenue

6.46.6———

Gemzar revenue

—4.8———

Zyprexa revenue

—7.1———

K-CAB co-promotion revenue

—27.9———

Oncology revenue (KRW Bn)

Oncology revenue (KRW Bn)H1 2023H1 2026

Oncology franchise

106.1130.5

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

627.3760.5859.61,017.11,017.4

Revenue growth (%)

11.6421.2313.0418.320.03

Cost of revenue (KRW Bn)

362.3453.3506.2653.8645.1

Gross profit (KRW Bn)

264.9307.2353.4363.4372.3

SG&A (KRW Bn)

171.7192.4214.1217.1216.3

Advertising expense (KRW Bn)

40.544.145.447.945.2

R&D expense (KRW Bn)

39.141.747.351.565.1

Amortisation of intangibles (KRW Bn)

6.09.718.818.617.9

Operating income (KRW Bn)

41.456.667.770.565.1

EBITDA (KRW Bn)

73.594.2112.1113.3108.6

Interest expense (KRW Bn)

4.56.19.59.011.6

FX gain/loss (KRW Bn)

2.410.91.019.0-0.2

Gain/loss on investments (KRW Bn)

32.3-5.7-1.4-17.411.9

Pre-tax income (KRW Bn)

70.758.956.363.069.8

Income tax (KRW Bn)

27.616.916.1-6.75.5

Net income attributable (KRW Bn)

43.041.940.269.664.3

EPS basic (KRW)

6896366101,020766

EPS diluted (KRW)

6836346101,016766

Dividend per share (KRW)

100100100100160

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Gross margin (%)

42.2440.3941.1135.7336.59

Operating margin (%)

6.617.447.886.936.40

EBITDA margin (%)

11.7212.3913.0411.1410.67

Net margin (%)

6.865.514.686.856.32

R&D / revenue (%) (c)

6.245.485.505.066.40

Effective tax rate (%)

39.0328.7628.58—7.94

Income Statement

Metric (KRW Bn)Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Revenue

240.6251.5280.0245.3255.4279.6

Operating income

10.925.429.4-0.620.223.8

Net income

0.38.9—21.1—24.1

Balance Sheet and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (KRW Bn)

828.6892.4915.51,164.11,387.9

Cash and equivalents (KRW Bn)

150.716.116.5187.2227.6

Cash and short-term investments (KRW Bn)

201.417.920.1191.8254.7

Accounts receivable (KRW Bn)

106.6137.5158.9189.2172.1

Inventory (KRW Bn)

111.0164.6189.8229.3219.4

Long-term investments (KRW Bn)

57.5129.2134.6143.8332.3

Goodwill and intangibles (KRW Bn)

92.8183.6172.9155.0143.7

Short-term debt incl. current LTD and leases (KRW Bn) (c)

26.3113.751.642.370.9

Long-term debt incl. leases (KRW Bn) (c)

189.294.6152.6126.3259.1

Total debt (KRW Bn)

215.5208.3204.2168.6330.0

Net debt (KRW Bn) (c)

14.1190.3184.2-23.275.3

Shareholders' equity (KRW Bn)

474.3516.4549.3784.5845.5

Working capital (KRW Bn)

281.460.9176.6385.5405.7

Book value per share (KRW)

7,1927,8338,3319,34310,008

Cash Flow and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (KRW Bn)

60.227.842.280.6133.2

Change in working capital (KRW Bn)

-10.1-62.0-55.9-43.629.3

Capital expenditure (KRW Bn)

16.120.315.012.822.2

Free cash flow (KRW Bn)

44.07.527.267.7110.9

FCF margin (%)

7.020.993.166.6610.90

Purchase of intangibles (KRW Bn)

43.1102.78.07.27.7

Dividends paid (KRW Bn)

4.56.66.66.88.4

Share buybacks (KRW Bn)

4.70.2000

Equity issued (KRW Bn)

98.500175.00

Net debt issued/repaid (KRW Bn)

23.7-8.6-6.1-39.8144.1

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROE on year-end equity (%) (c)

9.078.117.328.887.61

ROA on year-end assets (%) (c)

5.194.694.395.984.63

ROIC (EBIT x 0.75 / equity + debt − cash) (%) (c)

6.376.016.926.945.30

Current ratio (x) (c)

2.801.221.882.612.59

Debt / equity (x) (c)

0.450.400.370.210.39

Net debt / EBITDA (x) (c)

0.192.021.64-0.210.69

Interest coverage EBIT/interest (x) (c)

9.269.247.097.835.62

Asset turnover (x) (c)

0.760.850.940.870.73

Days sales outstanding (c)

62.066.067.567.961.7

Days inventory outstanding (c)

111.8132.6136.9128.0124.2

Days payables outstanding (c)

62.072.750.160.355.7

Cash conversion cycle (days) (c)

111.8125.9154.3135.6130.2

Region Overview

RegionFY2025

Domestic Korea revenue (KRW Bn) (c)

1,004.8

Export revenue (KRW Bn)

12.6

Export share of revenue (%) (c)

1.24

Revenue by Region

Interim exports (KRW Bn)H1 2025H1 2026

Total exports

3.913.1

Of which Taxotere

06.8

Revenue by Region (Annual)

Product / market20212022202320242025

Gelfos exports, mainly China (KRW Bn)

8.09.12.17.23.5

Share Price & Returns

Reference pointPrice (KRW)Source

30 Jul 2021 (post 1.2x bonus issue)

17,950

Daishin Securities, Aug 2021

24 Aug 2023

9,000

Shinhan Investment, Aug 2023

4 Nov 2024 allotment price

9,670

BioSpectator

31 Dec 2024 close

10,290

Alpha Distillery

31 Dec 2025 close

9,010

Alpha Distillery

14 Oct 2026 close

8,360

StockAnalysis

Performance (price only)

Value

—

1-year (52-week) change

−0.24% (StockAnalysis, 14 Oct 2026)

—

~3-year change (Aug 2023 → Oct 2026)

approx. −7% (computed from points above)

—

~5-year change (Jul 2021 → Oct 2026)

approx. −53% (computed; not adjusted for dividends)

—

YTD 2026 (31 Dec 2025 → 14 Oct 2026)

approx. −7% (computed)

—

Beta (5Y)

0.33—

50-day / 200-day moving average

KRW 8,727 / KRW 9,059

—

Valuation Multiples

MultipleBoryungPeer reference (Alpha Distillery median; May 2026)

P/E trailing

5.82 (inflated by FX/investment gains)

9.8

P/E forward

10.67—

EV/EBITDA

7.97—

EV/Sales

0.90—

P/S

0.660.74

P/B

0.791.28

P/FCF

5.61—

Dividend yield

1.91%—

Analyst Ratings & Targets

Broker / sourceDateRatingTarget (KRW)

SK Securities

19 May 2026

Buy

14,000

Alpha Distillery (AI research site; not a broker)

27 Jul 2026

Buy

11,500

Shinhan Investment (historical)

25 Aug 2023

Buy

13,000

FnGuide consensus Q2 2026

Jul 2026

—

Revenue KRW 257.6bn, OP KRW 20.9bn (actual beat on revenue)

Per-Share Data and Dividends & Capital Returns

MetricFY2021FY2022FY2023FY2024FY2025

Dividend per share (KRW)

100100100100160

Dividends paid (KRW Bn)

4.56.66.66.88.4

Payout ratio on EPS (%) (c)

14.515.716.49.820.9

Capital Markets

ItemDetail

Moody's / S&P / Fitch

Not rated (no international ratings publicly disclosed)

Current portion of LT debt (FY2025)

KRW 28.5bn

Short-term borrowings (FY2025)

KRW 38.0bn

Long-term debt (FY2025)

KRW 244.7bn

Total debt (30 Jun 2026)

KRW 388.9bn

Analyst Conclusions

Guidance and consensus

No formal FY2026 guidance was found. SK Securities (May 2026) cited LBA cost-of-goods improvements and Taxotere momentum in 2026–2027 behind its Buy call. Alpha Distillery models FY2026E revenue ~KRW 1,090bn and operating profit ~KRW 95bn, and FY2027E ~KRW 1,170bn / ~KRW 112bn. H1 2026 actuals (KRW 535.0bn revenue, KRW 44.0bn OP) are consistent with mid-to-high single-digit revenue growth before the full-year Taxotere effect.

Bull case

  1. Taxotere is accretive and contracted: A business with EUR 70m (2024) originator sales bought for ~EUR 170m (~2.4x sales), with China anchored by a USD 277m take-or-pay contract, should lift revenue and, once produced at Yesan, gross margin.

  2. Margins are inflecting: Q1 2026 OP +84.7% and H1 2026 OP +21.1% were achieved while still provisioning for Kanarb; a favourable appeal could reverse ~KRW 32bn of provisions.

  3. Cheap on assets and cash flow: P/B 0.79x, P/FCF 5.6x, EV/EBITDA ~8x — below peer medians — while CDMO contracts begin contributing in 2026–2027.

Bear case

  1. Kanarb erosion is structural: substance patent expired 2023; the use-patent suit was withdrawn; generics are ready; a final appeal loss means refunds plus permanently lower prices on ~16% of revenue.

  2. Balance-sheet and capital-allocation risk: net debt rose to KRW 254bn post-deal; ~KRW 93bn has gone into non-earning space assets; interest coverage has halved since FY2021.

  3. Minority-shareholder alignment: a discounted allotment to the owner's vehicle, a succession-driven parent merger, and a physical spin-off of the commercial arm have coincided with a ~53% share-price decline over five years.

Key catalysts and monitorables (next 12 months)

  • EGM vote on BPS (28 Oct 2026) and scale of appraisal-right exercises.

  • Q3 2026 results (est. 13 Nov 2026): first full quarter of Taxotere; Kanarb provision run-rate.

  • Seoul High Court ruling on the Kanarb price-cut appeal.

  • Ditaxel divestiture (deadline ~Dec 2026, extendable to ~Jun 2027).

  • Yesan oral-line EU-GMP/FDA cGMP/ANVISA inspections; Zyprexa CDMO exports from Q4 2026.

  • Taxotere manufacturing transfer timeline and country-by-country authorisation transfers.

  • Treasury-share use/cancellation decisions; FY2026 DPS.

  • Space-asset valuation marks (Axiom, Intuitive Machines).

Analyst verdict

Boryung is in the middle of its most consequential transformation since Kanarb's launch in 2011. The core thesis is straightforward: a domestically focused, mid-margin Korean drugmaker is converting itself into an owner-operator of originator brands with captive EU-GMP manufacturing and genuinely international revenue. The Taxotere acquisition is the proof point — it is the first time a Korean company has bought a big-pharma originator oncology business for global sale, and the Yifan contract de-risks the largest territory within four months of closing. CDMO contracts with Lotus, Cheplapharm and Zuellig show that the LBA playbook creates second-order revenue from the same plants.

Against that, the domestic earnings base is under credible pressure. Kanarb, the company's only proprietary blockbuster, faces a court-validated price cut and imminent generic competition, and management has not yet shown that Kanarb Jet and other combinations can offset that erosion in absolute terms. Reported profitability is noisy: FY2025 was restated downward, and trailing net income is flattered by FX and investment gains that should be excluded from any valuation.

Valuation reflects much of this. At roughly 0.8x book, ~8x EV/EBITDA and a double-digit FCF yield on TTM figures, the market is pricing Boryung as an ex-growth domestic generic company. If Taxotere and CDMO lift group operating margin toward 9–10% by FY2027, the shares look undervalued relative to Korean peers. The discount, however, is not purely about earnings: governance — a controlling-family chain consolidated through succession transactions, a combined chair/CEO, a minority-independent board, and sizeable space investments outside the core business — warrants a persistent discount until minority-shareholder returns improve (e.g., cancelling rather than reissuing treasury stock).

Net view: fundamentally improving, structurally under-owned, governance-discounted. The Kanarb appeal outcome and the first two full quarters of Taxotere are the decisive near-term data points.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackground / educationAgeCompensation

Jay (Jung-kyun) Kim

Representative Director, CEO; Board Chair

Boryung CEO since Mar 2022; sole CEO since 28 Feb 2025

Grandson of founder Kim Seung-ho, son of Kim Eun-sun; BS Industrial Engineering, University of Michigan; MS social & administrative pharmacy, Chung-Ang University; Samjong KPMG (2011); joined Boryung 2014; CEO Boryung Holdings 2019

Born 1985 (41)

—

Kim Sung-jin

Chief Strategy Officer; Inside Director

Inside director since Mar 2022; re-elected Mar 2025

Former head of Global Investment Center; led Taxotere, CDMO, strategy

—

FY2025 total KRW 4,064.75m, incl. 400,000 restricted shares valued at KRW 3,460m (Daily Pharm, Sept 2026)

Park Yoon-sik

Vice President

———

Received RSA in 2025 (amount not disclosed)

Jack (Dong-ju) Lim

Head, New Portfolio Investment Group; CEO, BRAX Space

Joined 2021

Oversaw Axiom Space investment

——

Chang Doo-hyun

Former co-CEO (pharma operations)

2022 – resigned 28 Feb 2025

Professional manager

——

“—” = not publicly disclosed.

Governance Overview

ItemDetail

Composition

4 executive directors and 2 independent directors (company governance page, data as of c.2022)

Chair

Jay Kim (CEO) — chair and CEO roles combined since 2022

Committees

Not publicly disclosed in sources reviewed; ESG performance reported regularly to the board; a Chief Risk Officer function exists (KCGS/press summaries, Nov 2025)

Independence assessment

Minority independent board (2 of 6), combined chair/CEO, controlling owner — weak by international standards

Major Shareholders

HolderStakeSource

Boryung Holdings Co., Ltd.

~50.66% (18,097,207 shares transferred from Boryung Partners added to prior 29.71%)

Dealsite TV, May 2026

Boryung Holdings and related parties (10 persons)

64.78%

Alpha Distillery

Boryung Jungbo Foundation

0.7% (471,670 shares)

Company governance page (older data)

Treasury shares

~1.6m shares (approx., after 1m cancellation and partial 2026 purchases)

—

Foreign investors

~4.89%

Alpha Distillery

Insiders (S&P definition)

10.15%

StockAnalysis/S&P Global

Institutions

7.10%

StockAnalysis/S&P Global

Free float

~28.3m shares

StockAnalysis/S&P Global

Competitive Landscape

Competitors by Segment

AreaCompetitors

Korean ETC (broad)

Yuhan, GC Biopharma, Chong Kun Dang, Daewoong Pharmaceutical, Hanmi Pharmaceutical, HK inno.N, JW Pharmaceutical, Dong-A ST, Ildong, Daewon, Kwangdong (scale peer)

ARB hypertension / Kanarb generics

Dongkook (Pimamono), Daewoong Bio (Kanaden), Alliko (Alkana), Korea Hutex (Hunab); originator ARBs from multinationals; Hanmi Amosartan family, Chong Kun Dang Telmi series

Docetaxel / cytotoxics in Korea

Generic docetaxel suppliers (post-divestiture owner of Ditaxel); other cytotoxic generic makers

Taxotere global markets

Local docetaxel generic producers in China, EU, LatAm

Legacy brand consolidation (global)

Cheplapharm (also a partner), other originator-brand acquirers

CDMO (cytotoxic/oral)

Korean and Asian CDMOs (not individually verified)

Peer Comparison FY2025

CompanyRevenue FY2025Operating profit FY2025Operating margin (%)

Yuhan

2,186.6104.44.8

GC Biopharma

1,991.369.13.5

Chong Kun Dang

1,692.480.64.8

Kwangdong

1,659.531.01.9

Daewoong Pharmaceutical

1,570.9196.812.5

Hanmi Pharmaceutical

1,547.5257.816.7

HK inno.N

1,063.2110.910.4

Boryung

1,017.465.16.4

Peer Comparison FY2025 — Revenue FY2025

MetricBoryungHanmiDaewoongHK inno.N

Revenue FY2025 (KRW Bn)

1,017.41,547.51,570.91,063.2

Revenue growth FY2025 (%)

0.03———

Operating margin FY2025 (%)

6.416.712.510.4

R&D intensity (%)

6.4———

Key proprietary franchise

Kanarb (off-patent)

Rosuzet/Amosartan family

Fexuclue/Envlo

K-CAB (P-CAB)

“—” = not publicly disclosed.

Company Snapshot

$716M

Revenue

1,553

Employees

1957

Founded

Seoul, South Korea

Headquarters

SWOT Analysis

Strengths

  • Scale achieved: Revenue doubled from ~KRW 500bn (2019) to KRW 1,017bn (FY2024–FY2025) (Daily Pharm, Feb 2025).
  • Proprietary cardiovascular franchise: Kanarb family ~KRW 151bn in FY2024, ~15–16% of revenue, with Q2 2026 underlying growth of 23% ex-provision.
  • Proven LBA execution: Gemzar, Zyprexa, Alimta all in-sourced; H1 2026 oncology revenue KRW 130.5bn.
  • Global-grade manufacturing: Yesan EU-GMP (2023), capacity 870m tablets and 6m vials, ~3x Ansan.
  • Cash generation: FY2025 FCF KRW 110.9bn; TTM FCF KRW 125.3bn.
  • Committed controlling shareholder: KRW 175bn owner capital in Nov 2024; ESG rating A two years running (KCGS 2024, 2025).

Weaknesses

  • Low margins: FY2025 operating margin 6.4% vs. 10.4–16.7% for HK inno.N, Daewoong, Hanmi.
  • Domestic concentration: exports only KRW 12.6bn (1.2% of revenue) in FY2025.
  • Thin novel pipeline: no late-stage proprietary NCE disclosed beyond BR101801 (status unconfirmed).
  • Long cash conversion cycle: ~130 days (FY2025, computed).
  • Governance: combined chair/CEO, 2 of 6 independent directors; KCGS governance sub-score only B+ in 2024.
  • Thin sell-side coverage: only one broker (SK Securities) actively publishing a target price in 2026 (Alpha Distillery).

Opportunities

  • Taxotere China: USD 277.1m Yifan contract, ≥90% take-or-pay, 7 years.
  • Taxotere margin uplift once production moves to Yesan.
  • CDMO pipeline: Cheplapharm (46 countries, Q4 2026), Zuellig (2027), Lotus (2026).
  • Oncology generics: Lenvanib (2025), Ibrance generic, Cabometyx generic (2030).
  • BPS in-licensing platform: 42 new products targeted by 2030, >10% market share.
  • Kanarb appeal: a win would reverse cumulative provisions (~KRW 32bn reported by Daily Pharm).

Threats

  • Kanarb clawback: final loss crystallises refunds and permanently lowers price (cuts of ~30% per strength).
  • Generic erosion: multiple fimasartan generics ready to launch; use-patent suit withdrawn July 2026.
  • Leverage: net debt KRW 253.8bn (Jun 2026), ~2.1x TTM EBITDA; interest coverage fell from 9.3x (FY2021) to 5.6x (FY2025).
  • Space asset impairment: ~KRW 111.5bn book value of pre-revenue/volatile space assets (Jun 2026).
  • Regulatory/integration risk: 19-country Taxotere marketing authorisation transfers; KFTC divestiture deadline (~Dec 2026, extendable).
  • Minority-shareholder risk: physical spin-off and prior discounted allotment (KRW 9,670/share, 10% discount, to owner vehicle) create perceived value-transfer concerns.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
31 Mar 2025First AGM under sole CEO; space positioned as second growth pillarStrategic signalling
29 Apr 2025Q1 2025: revenue KRW 240.6bn (+3%), OP KRW 10.9bn (−33.1%), NI KRW 0.3bnR&D/advertising and Alimta in-sourcing costs
May 2025Kanarb generics listed for reimbursement (Dongkook, Daewoong Bio, Alliko, Korea Hutex, others)Trigger for mandatory price cut
May 2025Lenvanib reimbursed on Lenvima substance-patent expiryOncology generic launch
Jun 2025MOHW notifies Kanarb price cut of up to ~30% per strength (as above); Boryung sues and obtains stayMajor earnings risk
17 Jul 2025Cheplapharm Zyprexa CDMO (up to 46 countries)First oral CDMO
30 Sept 2025Taxotere global acquisition signed (up to EUR 175m)Transformational
30 Oct 2025Zuellig Alimta CDMO for 7 SE Asian countriesThird CDMO
Nov 2025KCGS ESG rating A for second year (Social A+)ESG standing
2025RSA awards to CSO and VPCompensation
12 Feb 2026Seoul Administrative Court rules against Boryung on Kanarb price cutLegal setback
13 Feb 2026FY2025 preliminary results restated: revenue −KRW 18.6bn, OP to KRW 65.1bn, Q4 OP −KRW 0.6bnEarnings shock; appeal planned
11 Mar 2026Boryung Holdings board approves absorption of Boryung PartnersSuccession
Mar 2026FY2025 DPS raised to KRW 160 (ex-date 29 Dec 2025)Shareholder return
1 May 2026Holdings–Partners merger effective; Holdings >50% of BoryungControl consolidated
May 2026Seoul High Court grants stay of Kanarb price cut pending appeal rulingCash clawback deferred (Alpha Distillery)
18 May 2026Alimta supply to Lotus beginsFirst CDMO revenue
May 2026Kanarb Jet launchedKanarb lifecycle
19 May 2026Q1 2026: revenue KRW 255.4bn (+6.2%), OP KRW 20.2bn (+84.7%); SK Securities Buy, TP KRW 14,000Margin inflection
29 May 2026Partial invalidation of Cabometyx patentPipeline
2 Jun 2026Taxotere closing; global sales beginRevenue from June
4 Jun 2026KFTC conditional clearance; Ditaxel divestiture orderedRemedy
8 Jun 2026Gelfos M 12-pack launch (affiliate BCH)OTC
12 Jun 2026KRW 20bn buyback for employee stock awardsCapital return / retention
13 Jul 2026Kanarb use-patent lawsuit withdrawnEases generic entry
1 Aug 2026Atozet exclusive distribution startsPortfolio
6 Aug 2026Q2 2026: revenue KRW 279.6bn (+11.2%, record), OP KRW 23.8bn (−6.2%), NI KRW 24.1bn (+171%); H1 recordsTaxotere and CDMO contribute
Aug 2026Kanarb Jet reported at 42% share within one month (Daily Pharm headline)New product traction
4 Sept 2026H1 2026 exports KRW 13.1bn, 3.3x YoY; Taxotere KRW 6.8bnGlobalisation
15 Sept 2026BPS physical spin-off approved by boardRestructuring
22 Sept 2026Yifan Taxotere China supply contract, USD 277.1m / 7 yearsLargest supply contract in company history
28 Oct 2026 (scheduled)EGM on BPS spin-offKey vote
13 Nov 2026 (estimated)Q3 2026 resultsFirst full Taxotere quarter

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

8 charts
Income Statement: Revenue & Gross Profit: Revenue rose from KRW 627.3 Bn in FY2021 to KRW 1,017.4 Bn in FY2025.
Boryung Corporation — Income Statement: Revenue & Gross Profit
Series (KRW Bn)FY2021FY2022FY2023FY2024FY2025
Revenue627.3760.5859.61,017.11,017.4
Cost of revenue362.3453.3506.2653.8645.1
Gross profit264.9307.2353.4363.4372.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. StockAnalysis.com / S&P Global Market Intelligence — Boryung income statement, balance sheet, cash flow, statistics (accessed Oct 2026) · stockanalysis.com · stockanalysis.com · stockanalysis.com
  2. Dealsite — Q1 2025 results (Apr 2025) · CEO change (Feb 2025) · Kanarb court loss and restatement (Feb 2026) · Q2 2026 results (Aug 2026) · Cheplapharm CDMO (Jul 2025) · Zuellig CDMO (Oct 2025) · Yesan capacity (Nov 2025) · ESG A rating (Nov 2025) · BPS (Sept 2026)
  3. Daily Pharm — Taxotere deal (Oct 2025) · FY2024 results · Nov 2024 allotment · Kanarb provision · Q2 2026 · exports · space/spin-off/RSA (Sept 2026) · BPS filing · Yifan contract · patents · Gelfos exports
  4. Herald Corp / Seoul Economic Daily — Taxotere closing and KFTC (Jun 2026) · mbiz.heraldcorp.com · en.sedaily.com
  5. Concurrences — KFTC conditional clearance (Jun 2026)
  6. Hankyung — Taxotere 2024 global sales (Sept 2025)
  7. Medical Times — BPS spin-off (Sept 2026) · medicaltimes.com
  8. Dealsite TV — Holdings/Partners merger (May 2026)
  9. The Fact — merger (Apr 2026)
  10. NewsSpace — Boryung Holdings FY2025 audit (2026)
  11. KED Global — BRAX JV (Jan 2024) · H1 2023 and LBA history (Jul 2023)
  12. Axiom Space press release (Jan 2024)
  13. Bizhankook — Axiom investment history (2025)
  14. HuffPost Korea — FY2025 peer results (Feb 2026) · H1 2026 (Aug 2026)
  15. BizWatch — FY2025 rankings (Feb 2026) · ESG 2024
  16. SBS Biz / Money Today / Asia Economy — H1 2026 results (Aug 2026) · mt.co.kr
  17. StockHub (SK Securities summary, May 2026)
  18. Medigate News — name change (Mar 2022)
  19. Company IR (2019) and governance page
  20. IBK Securities, Daishin Securities, Shinhan Investment research PDFs (2021–2024) via alphasquare.co.kr
  21. Alpha Distillery (AI-generated research) · alphadistill.com
  22. iNews24 — Kanarb FY2024 sales
  23. Seoul Shinmun — corporate history (2015)
  24. BioSpectator — Holdings creation (2017) and 2024 allotment · biospectator.com

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.